Comparative bioavailability of two immediate release tablets of cisapride in healthy volunteers

  • M. T. Maya
  • C. R. Domingos
  • M. T. Guerreiro
  • A. P. Filipe
  • J. A. Morais


Relative bioavailability of cisapride was investigated after oral administration of a test versus a reference formulation of immediate release tablets of cisapride, both with 10 mg per unit. The study was conducted in a two-way cross-over design, as a single dose open-label randomised trial. The two formulations were administered in two treatment days, separated by a washout period of 6 days, in fasted subjects who received one single oral dose of 20 mg of one study medication of cisapride as two 10 mg tables. Multiple samples were collected over 24 h post-dosing. Plasma samples were assayed for cisapride using a selective and sensitive high-performance liquid chromatography (HPLC) method with UV detection. The pharmacokinetic parameter values (mean±RSD%) of cisapride as the test formulation were: AUC0−∞=329±20.9 ng.h/ml, Cmax=52.8±22.6 ng/ml, tmax=1.26±22.0 h and t1/2=4.08 \+-15 h. Following administration of the reference formulation the values obtained for the same parameters were: AUC0\t-\t8=317\+-19.2 ng.h/ml, Cmax=49.2\+-21.3 ng/ml, tmax=1.38\+-30.1 h and t1/2=4.52\+-24.8 h. These results show that the two cisapride formulations can be considered as bioequivalent, with respect to the above mentioned parameters.


Cisapride human pharmacokinetics bioavailability 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    McCallum R. W., Prakash C., Campoli-Richards D.M., Goa K.L. (1988): Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs, 36, 652–681.CrossRefPubMedGoogle Scholar
  2. 2.
    Van Peer A., Verlinden M., Woestenborghs R. et al. (1988): Clinical pharmacokinetics of cisapride. In: Johnson and Lux (Eds). Progress in the treatment of gastrointestinal motility disorders. The role of cisapride. Amsterdam: Excerpta Medica, 23–29.Google Scholar
  3. 3.
    Anon. (1994): Cisapride. An update. Drugs, 47.Google Scholar
  4. 4.
    Barone J.A., Yih-Chain Huang, Bierman Robert H. et al. (1987): Bioavailability of three oral dosage forms of cisapride, a gastrointestinal stimulant agent. Clin. Pharm., 6, 640–645.PubMedGoogle Scholar
  5. 5.
    Meuldermans W., Van Peer A., Hendrikx J. Lauwers W. et al. (1988): Excretion and biotransformation of cisapride in dogs and humans after oral administration. Drug Metab. Dispos., 16, 403–409.PubMedGoogle Scholar
  6. 6.
    Maya M.T., Belchior M., Domingos C., Guerreiro M.T., Morais J.A. (1998 Determination of cisapride in human plasma by high-performance liquid chromatography. Submitted.Google Scholar
  7. 7.
    Retting Z.R. (1989): Genérica: a software package for statistical analysis of bioavailability studies, v 3.1 Coesfeld.Google Scholar
  8. 8.
    Westlake W.J. (1979): Statistical aspects of comparative bioavailability trials. Biometrics, 35, 273–280.CrossRefPubMedGoogle Scholar
  9. 9.
    Schuirmann D.J. (1987): A comparison of two one-sided tests procedure and the power approach to assessing the bioequivalence of average bioavailability. J. Pharmacokinet. Biopharm., 15, 657–680.CrossRefPubMedGoogle Scholar
  10. 10.
    Fluehler H., Grieve A.P., Mandallaz D., Mau J., Moser H.A. (1983): Bayesian approach to bioequivalence assessment: an example. J. Pharm. Sci., 72, 1178–1181.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1998

Authors and Affiliations

  • M. T. Maya
    • 1
  • C. R. Domingos
    • 2
  • M. T. Guerreiro
    • 2
  • A. P. Filipe
    • 3
  • J. A. Morais
    • 2
  1. 1.Centro de Patogenese MolecularFaculdade de Farmácia da Universidade de LisboaPortugal
  2. 2.Faculdade de Farmácia da Universidade de LisboaPortugal
  3. 3.Tecnimede SAPortugal

Personalised recommendations